J. Charles Eldridge

Chronic effects of atrazine on estrus and mammary tumor formation in female Sprague-Dawley and fischer 344 rats

The chronic effects of dietary administration of atrazine at levels as high as 400 ppm on selected endocrine and tumor profiles were evaluated in Fischer 344 and Sprague-Dawley female rats. The study showed that lifetime dietary administration of atrazine at a maximum tolerated dose (MTD) to Sprague-Dawley female rats caused (1) lengthening of the estrous cycle, (2) increased number of days in estrus or under the influence of exposure to estrogen, (3) earlier onset of galactocele formation, and (4) earlier onset of mammary and pituitary tumor formation but not an increased incidence of mammary and pituitary tumors when compared to concurrent control rats. Fischer 344 female rats fed atrazine at an MTD exhibited slightly lengthened estrous cycles, but no effects were observed on estradiol or progesterone levels, or on the onset or incidence of mammary tumors. These results support a hypothesis that high-dose atrazine administration in Sprague-Dawley females is related to an acceleration of age-related endocrine changes leading to an earlier onset and/or increased incidence of mammary tumors. This endocrine-mediated response, which appears to be unique to the Sprague-Dawley female rat, occurs only at or above a threshold dose (the MTD) that interferes with normal estrous cycling, promoting prolonged exposure to endogenous estrogen.

Hypothesis for mammary tumorigenesis in Sprague-Dawley rats exposed to certain triazine herbicides

The symmetrical triazine herbicides have been used for the preemergence control of broadleaf weeds for nearly three decades. Recently, certain members of this class, primarily the chlorotriazines (substituted in the 2 position), have been shown to evoke an increased incidence of mammary tumors in female Sprague-Dawley rats. This response was noted when these chemicals were administered in the diet for 2 yr, and most often at dietary feeding levels at or above the maximum tolerated dose (MTD). At levels exceeding the MTD the health of these animals was compromised, as manifested by toxicity-related reduced survival that was not associated with the occurrence of mammary tumors. Mammary tumors in rats frequently occur as a result of the influence of endogenous estradiol and prolactin. Those hormones, as well as progesterone, growth-stimulating, luteinizing, and follicle-stimulating hormones, were measured after 24 mo of dietary administration of the chlorotriazine, simazine. The plasma hormone pattern seen in aged female Sprague-Dawley rats administered 1000 ppm simazine in the diet for 24 mo resembled that noted for aged female controls, except that the difference was more pronounced in the simazine-treated group. These results suggest that prolonged exposure of Sprague-Dawley females to excessive levels of triazines affects the neuroendocrine system, which in turn alters the pathology of the mammary gland. These changes are comparable to those that occur naturally as the rat ages. Changes in neuroendocrine control could result in the expression of an earlier onset and/or an increased incidence of mammary tumors, which already occur at a high spontaneous rate in aging Sprague-Dawley female rats.

The Glucocorticoid Hypothesis of Age-Related Hippocampal Neurodegeneration: Role of Dysregulated Intraneuronal Calcium

The hippocampal formation is among the brain structures most vulnerable to normal brain aging in and humans.3~~ The hippocampus also demonstrates severe damage in Alzheimer’s disease (AD) and related disorder^,^,^ and damage to this region is believed to contribute substantially to the cognitive/mnemonic manifestations of that disease. A number of hypotheses for mechanisms underlying the ageand/or AD-dependent pathologic degeneration of the hippocampus have been presented (cf. Refs. 3,7,8 for discussion), but one continuing hypothesis suggests a central role for glucocorticoid (GC) steroids of the adrenal gland.g Although originally proposed during the late 1970~,’~J’ the GC hypothesis has been subjected to extensive testing and still appears to be one of the few currently viable explanations of mammalian brain decline with aging. However, the hypothesis has not remained unmodified since it was initially proposed. Ongoing experimentation on the role of corticosteroids in brain aging has led to a progression of evolving concepts regarding specific mechanisms underlying interactions of corticosteroids and the brain aging process. The present paper discusses briefly some of the developmental history of the GC hypothesis and summarizes recently obtained evidence that appears to warrant further modifications of the hypothesis. The new evidence suggests a greater emphasis on (a) a need to consider an apparently important age-related susceptibility to GC effects on the brain, and (b) the role of altered intracellular calcium homeostasis as a possible key mechanism mediating GC-related neurotoxicity and brain aging.

Short‐term effects of chlorotriazines on estrus in female Sprague‐Dawley and Fischer 344 rats

Atrazine or simazine (s-chlorotriazines) was administered by gavage daily for 2 wk to female Sprague-Dawley and Fischer 344 rats at oral doses of 100 or 300 mg/kg to evaluate effects on body, ovary, uterus, and adrenal weights, estrous cycle stages, vaginal cytology, and plasma hormone (estradiol, progesterone, prolactin, and corticosterone) levels. Significant reductions in body weights of both Sprague-Dawley and Fischer 344 female rats at both dose levels were accompanied by a significant reduction in ovarian and uterine weights, and a decrease in circulating estradiol levels. The magnitudes of the effects were less in Fischer 344 rats than in Sprague-Dawley rats, and the effects of simazine were less pronounced than those of atrazine at the same dose. A maximum tolerated dose (MTD: > or = 10% body weight reduction) was estimated to be 100 mg/kg for atrazine and 300 mg/kg for simazine for both stains. The Sprague-Dawley female rats exhibited a treatment-related lengthening of the estrous cycle and an increased number of days characterized by cornified epithelial cells. This resulted in a greater percent of the cycle days spent in estrus and reduction in the percent of the cycle days spent in diestrus. Atrazine-dosed Fischer 344 females also exhibited a significant trend toward cycle lengthening, but this was due to reduction in the percent of cycle spent in estrus and a concomitant increase in diestrual days. These findings suggest that treatment with doses of triazine at or above the MTD may result in prolonged exposure to endogenous estrogen in the Sprague-Dawley but not the Fischer 344 rat. These changes may account for the observed earlier onset and/or increased incidence of mammary tumors in chlorotriazine-treated female Sprague-Dawley rats. This strain of rat is already known to be prone to a substantial development of mammary tumors with advancing age, while the Fischer 344 strain is not as likely to exhibit this response.

Impaired up-regulation of type II corticosteroid receptors in hippocampus of aged rats

Several recent investigations have reported a decline of rat hippocampal corticosteroid-binding receptors (CSRs) with aging. This decline has been proposed to be an initial cause (through disinhibition) of the elevated adrenal steroid secretion that apparently occurs with aging; however, it could instead be an effect of corticoid elevation (through down-regulation). In order to assess the effects of age on CSR biosynthetic capacity in the absence of down-regulatory influences of endogenous corticoids, as well as to study aging changes in CSR plasticity, we examined the up-regulation of hippocampal CSR that follows adrenalectomy (ADX). The rat hippocampus contains at least two types of CSR binding and differential analysis of types I and II CSR was accomplished by selective displacement of [3H]corticosterone with RU-28362, a specific type II agonist. In young (3 months old) Fischer-344 rat hippocampus, up-regulation of type II binding above 2-day ADX baseline was present by 3-7 days and increased still further by 8-10 days post-ADX; type I CSR density did not change significantly between 1 and 10 days post-ADX. However, in aged (24-26 months old) rats, type II CSR up-regulation did not occur over the 10 day post-ADX period. Thus, the age-related impairment of type II up-regulation may reflect an intrinsic deficit in CSR biosynthesis or lability that is independent of the acute endogenous adrenal steroid environment.

The mammary tumor response in triazine-treated female rats: a threshold-mediated interaction with strain and species-specific reproductive senescence.

Triazine herbicides are among the most heavily used agricultural pesticides. Although they possess a very low acute toxicity in animals, a mammary tumor response has been consistently observed in Sprague-Dawley (SD) female rats following chronic oral dosing of atrazine and simazine at and above maximum tolerated doses. However, a substantial collection of detailed research has clearly shown that triazines are not genotoxic or mutagenic, nor do they possess estrogenic agonist activity that might promote mammary tumor growth. Examination of estrous cycling records of atrazine-treated SD rats revealed a premature appearance of persistent estrous episodes, beyond the prevalent occurrence normally seen in untreated, aging SD rats. A significant correlation has been found between early or severe estrous cycle disruption of atrazine-treated rats and the early appearance of mammary tumors. In studies using SD female rats fed atrazine for 6 months, then ovariectomized and administered an estrogen-containing silastic s.c. implant, a deficient luteinizing hormone surge was observed at a 400 parts per million (ppm) dose, but not at 25 or 50 ppm. Because SD rats exhibiting persistent estrus also have a prolonged elevation of estrogen secretion, it is proposed that the triazine-associated mammary tumor response is promoted by the test animals own estrogen from ovarian follicles that fail to ovulate because gonadotropin surge sufficiency is blocked by the high dose of herbicide. It is further proposed that, because reproductive senescence in SD rats is fundamentally different from menopause in women, the animal response to dosing, as well as the enormous requisite dosing level, establishes a safety margin of very low risk to human health from this mode of action.

Ethanol consumption in the female Long-Evans rat: a modulatory role of estradiol.

The examination of various gonadal hormone manipulations on ethanol intake in human subjects and in rodent models has resulted in disparate findings. In the present study, we examined the effects of ovariectomy and subsequent estradiol (E(2)) replacement on ethanol intake in a within-subject design, as well as assessed the relevance of reproductive status on the efficacy of an E(2) stimulus in eliciting consumption. Female Long-Evans rats (n = 24) were given access to 10% ethanol and water in a continuous-access paradigm. After establishment of baseline intake values, rats were divided into four groups: sham/placebo (Shm+P), sham/estradiol (Shm+E(2)), ovariectomized/placebo (Ovx+P), and ovariectomized/estradiol (Ovx+E(2)). Rats in the Ovx+P group were found to have a large and permanent decline in ethanol intake that persisted more than 3 months postsurgery. Administration of E(2) to Ovx+E(2) rats was associated with restoration of ethanol consumption to baseline levels. When Shm+E(2) and Ovx+E(2) groups were compared, reproductive status was found to be a determining factor in the efficacy of E(2) to elicit ethanol intake. Together, these findings provide evidence that ovarian hormones, particularly estradiol, exert activational effects on estrogen-responsive substrates to modulate ethanol consumption in the adult female rat.

Increased affinity of type II corticosteroid binding in aged rat hippocampus

Hippocampal tissue from young-mature (3-4 months old) and aged (24-26 months old) Fischer-344 rats was assessed for type I and type II corticosteroid binding in cytosol, using [3H]dexamethasone and selective inhibition of type II sites with nonradioactive RU-28362. Twenty-four hours after adrenalectomy, the Bmax and Kd of the receptor subtypes were measured by Scatchard analysis for individual animals. The binding capacity of each receptor type was significantly reduced in aged rats, as others have reported. In addition, however, the dissociation constant (Kd), was significantly reduced for type II receptor (young Kd = 2.14 nM vs aged Kd = 0.89 nM, P less than 0.005), indicating greater affinity of type II sites with aging. Affinity of type I sites was unchanged. The observation of increased type II affinity could help to explain the apparent paradox of why corticosteroid-dependent degenerative changes in hippocampal cells seem to accelerate in the later stages of aging, even though brain corticosteroid receptor capacity has been reported to decline or remain unchanged with aging.

Atrazine and Breast Cancer: A Framework Assessment of the Toxicological and Epidemiological Evidence

The causal relationship between atrazine exposure and the occurrence of breast cancer in women was evaluated using the framework developed by Adami et al. (2011) wherein biological plausibility and epidemiological evidence were combined to conclude that a causal relationship between atrazine exposure and breast cancer is “unlikely”. Carcinogenicity studies in female Sprague-Dawley (SD) but not Fischer-344 rats indicate that high doses of atrazine caused a decreased latency and an increased incidence of combined adenocarcinoma and fibroadenoma mammary tumors. There were no effects of atrazine on any other tumor type in male or female SD or Fischer-344 rats or in three strains of mice. Seven key events that precede tumor expression in female SD rats were identified. Atrazine induces mammary tumors in aging female SD rats by suppressing the luteinizing hormone surge, thereby supporting a state of persistent estrus and prolonged exposure to endogenous estrogen and prolactin. This endocrine mode of action has low biological plausibility for women because women who undergo reproductive senescence have low rather than elevated levels of estrogen and prolactin. Four alternative modes of action (genotoxicity, estrogenicity, upregulation of aromatase gene expression or delayed mammary gland development) were considered and none could account for the tumor response in SD rats. Epidemiological studies provide no support for a causal relationship between atrazine exposure and breast cancer. This conclusion is consistent with International Agency for Research on Cancer’s classification of atrazine as “unclassifiable as to carcinogenicity” and the United States Environmental Protection Agencys classification of atrazine as “not likely to be carcinogenic.”

Atrazine Interaction with Estrogen Expression Systems

More than 40 publications have described results of atrazine responses in 17 estrogen-dependent systems and in more than a dozen different reporter and estrogen receptor-binding studies in vitro. Results from these studies have consistently failed to demonstrate that atrazine acts as an estrogen agonist. Moreover, a variety of indices of estrogen-dependent activity, in models that encompass cell incubations to whole animals, have failed to respond to atrazine. Researchers in more than a dozen laboratories have examined rats, rat tissues, human and prokaryotic cells, in addition to tissues from reptile, fish, amphibian, avian, molluscan, and insect sources, without eliciting estrogenic-like responses from atrazine. In contrast, studies of atrazine ability to antagonize estrogen-mediated responses have yielded equivocal results. Results of several studies show inhibition of estrogen-like activities by atrazine, yet many other tests have yielded negative results. Generally, in vivo models have more consistently shown that atrazine inhibits estrogen-mediated responses, whereas in more specific in vitro systems, inhibition is seldom observed. The implication is that in vivo effects of atrazine may result from inhibition of factors that are indirectly connected to the genomic interaction of estrogen (e.g., at the receptor). Potential targets of atrazine may be downstream of the ligand-receptor binding event. Atrazine may also interact with other, less specific, factors that are necessary for the completion of the estrogen-mediated response. Moreover, the apparent inhibition of cytosolic-ER binding by atrazine may, similarly, be relatively nonspecific. Observed inhibitory responses occur only at extreme doses or concentrations, i.e., several orders of magnitude greater than the level of estradiol presence in each test system. It is probable that the inhibitory effects result from very low affinity and/or low specificity interactions, which are unlikely to occur in nature. We conclude that atrazine is not an estrogen receptor agonist, but it may be a weak antagonist, when present at a high concentration under conditions of disequilibrium with estrogen. These conditions are not expected to occur as a result of normal environmental exposure.